Sanofi buying back $1B-plus in stock; Actos suits consolidated in Louisiana;

@FiercePharma: Bristol will have a tough time replacing 'string of pearls' strategist Levin, Bloomberg says. Story | Follow @FiercePharma

> Sanofi ($SNY) repurchased €1.074 billion worth of its own shares in 2011, or about 1.61% of its capital, at an average price of €49.6 euros per share. News

> Actos-related liability lawsuits against Takeda Pharmaceutical will be consolidated in one federal court in Louisiana, a multidistrict litigation panel determined. Item

> Pfizer's ($PFE) Prevnar 13 won FDA approval for people 50 years of age and older to prevent pneumonia and other diseases caused by Streptococcus pneumoniae. Release

> Lundbeck said its new epilepsy drug Onfi is now available in the U.S. Story

> India's Lupin won FDA approval for fenofibrate tablets for use as a dietary supplement; they're a generic version of Abbott Laboratories' ($ABT) prescription drug Tricor. Piece

> India's Dr. Reddy's Laboratories launched a pain relief cream, Supamove, that it licensed from Cymbiotics. Report

Biotech News

@FierceBiotech: FDA dishes out long-awaited guidance on social media. Article | Follow @FierceBiotech

@JohnCFierce: In case you missed last week's news, Alexion scoops up promising rare disease drug in $1.08B Enobia buyout. Story | Follow @JohnCFierce

@RyanMFierce: Accelrys paying $35M cash in VelQuest buyout, expanding from R&D software to tech for drug manufacturers. Release | Follow @RyanMFierce

> Aveo cancer drug beats Nexavar in risky PhIII face-off. Article

> Alexion scoops up rare disease drug in $1.08B Enobia buyout. News

Pharma Manufacturing News

> Flu vax tool aids strain identification, timing. Story

> Hospira enters angry-investor phase of remediation. Article

> Ben Venue lengthens remediation timeline. Item

> Infant pain reliever dosing 'fix' shows label limitations. Report

> Rockline quietly recalls contaminated wipes. News

> H&P/Triad, under decree, will recondition seized wipes. More

Biotech Research News

> Fish oil wipes out leukemia in mice. News

> Researchers decode some kidney cancer secrets. Item

> Johns Hopkins tapping genomes to find out why so many African-Americans get asthma. News

Biotech IT News

> FDA dishes out long-awaited guidance on social media. Article

> Poor patient recruitment cited in call for trial disclosures. Story

And Finally...
Drug-resistant TB may be caused by patients with faster-than-normal metabolism rather than inconsistent dosing, a new study suggests. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.